Loading...
The Neurokinin-1 Receptor Antagonist Aprepitant, a New Drug for the Treatment of Hematological Malignancies: Focus on Acute Myeloid Leukemia
Acute myeloid leukemia (AML) is a heterogeneous hematological malignancy. To treat the disease successfully, new therapeutic strategies are urgently needed. One of these strategies can be the use of neurokinin-1 receptor (NK-1R) antagonists (e.g., aprepitant), because the substance P (SP)/NK-1R syst...
Na minha lista:
Main Authors: | , |
---|---|
Format: | Artigo |
Sprog: | Inglês |
Udgivet: |
MDPI AG
2020-06-01
|
Serier: | Journal of Clinical Medicine |
Fag: | |
Online adgang: | https://www.mdpi.com/2077-0383/9/6/1659 |
Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|